The enVista TORIC is the company’s first hydrophobic acrylic IOL for astigmatism correction. Its launch was announced at the 2012 Congress of European Society of Cataract and Refractive Surgeons in Italy.
The IOL received CE mark approval in the European Union in April 2012; it is not approved for sale in the United States.
“The new enVista TORIC lens is the latest innovation from Bausch + Lomb designed to meet the needs of both customers and patients,” said Cal Roberts MD, executive vice president and chief medical officer for Bausch + Lomb, in the release. “It extends the unique benefits of the enVista lens launched at ESCRS last year. The enVista lens is manufactured using a glistening-free, foldable hydrophobic acrylic IOL material developed by Advanced Vision Science, a Santen subsidiary. Together, our unique Advanced Optics technology, clinically proven glistening-free material, and superior rotational stability, deliver optimal outcomes to patients. The addition of this new lens to our portfolio means that Bausch + Lomb now offers surgeons a more complete range of IOLs to meet their patients’ needs.”
Bausch + Lomb’s world headquarters is in Rochester, N.Y.
Related Articles on Ophthalmology:
Massachusetts Eye and Ear Partners With Joslin Diabetes Center for Eye Care
UC Irvine Receives Grant to Help Create Stem Cell Treatments for Retinitis Pigmentosa
